Objective-AGT (Angiotensinogen) is the unique precursor of the renin-angiotensin system that is sequentially cleaved by renin and ACE (angiotensin-converting enzyme) to produce Ang II (angiotensin II). In this study, we determined how these renin-angiotensin components interact with megalin in kidney to promote atherosclerosis. Approach and Results-AGT, renin, ACE, and megalin were present in the renal proximal convoluted tubules of wild-type mice. Hepatocyte-specific AGT deficiency abolished AGT protein accumulation in proximal tubules and diminished Ang II concentrations in kidney, while renin was increased. Megalin was most abundant in kidney and exclusively present on the apical side of proximal tubules. Inhibition of megalin by antisense oligonucleotides (ASOs) led to ablation of AGT and renin proteins in proximal tubules, while leading to striking increases of urine AGT and renin concentrations, and 70% reduction of renal Ang II concentrations. However, plasma Ang II concentrations were unaffected. To determine whether AGT and megalin interaction contributes to atherosclerosis, we used both male and female low-density lipoprotein receptor −/− mice fed a saturated fat-enriched diet and administered vehicles (PBS or control ASO) or megalin ASO. Inhibition of megalin did not affect plasma cholesterol concentrations, but profoundly reduced atherosclerotic lesion size in both male and female mice. Conclusions-These results reveal a regulatory role of megalin in the intrarenal renin-angiotensin homeostasis and atherogenesis, positing renal Ang II to be an important contributor to atherosclerosis that is mediated through AGT and megalin interactions. 
T he renin-angiotensin system plays a pivotal role in the development of atherosclerosis. [1] [2] [3] AGT (angiotensinogen) is the sole substrate of this hormonal system, which is cleaved by renin to release Ang (angiotensin) I. Ang I is subsequently cleaved by ACE (angiotensin-converting enzyme) to produce Ang II. 4, 5 There is compelling evidence that genetical or pharmacological inhibition of the renin-angiotensin components reduces atherosclerosis through inhibition of Ang II production or action. 1, [6] [7] [8] [9] [10] However, it remains unclear where Ang II is produced to exert its proatherogenic effects.
AGT originating from liver, renin from kidney, and ACE from lung constitute the systemic renin-angiotensin system. This classic notion has been expanded by discovery of these components in many tissues and organs. 11 Kidney has all of the renin-angiotensin components required to produce Ang II, and it has the potential to be an important locus for Ang II production based on its concentrations in proximal convoluted tubule far exceeding those in plasma. [12] [13] [14] It is also well-documented that activation of renal Ang II contributes to the pathogenesis of hypertension and kidney disease, 13, [15] [16] [17] [18] but the role of Ang II produced in kidney to atherosclerosis has not been determined.
In kidney, hepatocyte-derived AGT is endocytosed into proximal convoluted tubule cells by megalin. 19 Megalin, also known as low-density lipoprotein-related protein 2 or gp330, is a multiligand endocytic receptor in the LDL (low densitylipoprotein) receptor family. [20] [21] [22] Present in polarized epithelial cells, 20, [22] [23] [24] megalin is most abundant along the apical aspect of proximal tubules, 23 where it is primarily responsible for reabsorption of some glomerular filtered substances. 24 Megalin also interacts with AGT and determines its homeostasis in kidney. 19, 25 The regulatory role of megalin in AGT homeostasis and renal Ang II production that contributes to atherosclerosis has not been explored. In the present study, we identified potent actions of megalin in intrarenal renin-angiotensin regulation and atherogenesis, which provide evidence for a novel concept that kidney is an important source to promote atherosclerosis through a megalin-mediated mechanism.
Materials and Methods
Detailed Materials and Methods are available in the online-only Data Supplement.
Animals
Generation of hepatocyte-specific AGT deficient mice has been reported in our previous studies. , Stock number 002207) were purchased from The Jackson Laboratory. C57BL/6J mice were fed a normal laboratory diet (Diet number 2918; Envigo). To induce atherosclerosis, LDL receptor −/− mice were fed a diet supplemented with saturated fat (milk fat 21% wt/wt) and cholesterol (0.2% wt/wt; Diet number TD. 88137; Envigo; termed Western diet) for 12 weeks. Eight-to 12-week old littermates, both male and female mice, were used for experiments reported in this manuscript following the recent ATVB Council statement. 28 Quantification and characterization of atherosclerosis followed the recent AHA statement and our standard protocols. 29, 30 All experiments were performed according to protocols approved by the Institutional Animal Care and Use Committee at the University of Kentucky (Protocol number 2006-0009 or 2015-2050).
Administration of Antisense Oligonucleotides
Control or megalin antisense oligonucleotides (ASOs) were provided by Ionis Pharmaceuticals Inc (Carlsbad, CA). Control ASOs showed no complementary binding to any known rodent mRNA including megalin. Optimal dose information (lowest dose with the maximal inhibition of megalin mRNA) of megalin ASOs was provided by Ionis Pharmaceuticals Inc for Gen 2.0 ASOs at 120 mg/kg body weight and Gen 2.5 ASOs at 6 mg/kg body weight, respectively. ASOs were administered via subcutaneous injections once a week prepared in sterile PBS.
Statistical Analysis
SigmaPlot Version 13 (Systat Software Inc) was used for statistical analyses. To compare continuous response variables between 2 groups, an unpaired 2-tailed Student t test was used for normally distributed variables that passed the equal variance test, and Mann-Whitney U test was performed for variables not passing either normality or equal variance test. To compare more than 2 groups, 1-way ANOVA followed by Holm-Sidak method was used for normally distributed variables that passed equal variance test and Kruskal-Wallis 1-way ANOVA on Ranks with Dunn method for variables not passing normality or equal variance test, respectively. P<0.05 was considered as statistically significant.
Results

Hepatocyte-Derived AGT Contributed to AGT Protein and Ang II Production in Kidney
AGT is present in many tissues and organs. 4, 31 In agreement with previous findings, 19 we found that hepatocyte-specific AGT deficiency (hepAGT −/− ) diminished renal AGT protein accumulation without affecting mRNA abundance of AGT in kidney ( Figure 1A ; Figures I and II in the online-only Data Supplement). Renin is an aspartyl protease, which cleaves AGT to release the decapeptide Ang I. Plasma renin concentrations were much higher in hepAGT −/− mice than their wild-type littermates. 26 Immunofluorescent staining showed that both AGT and renin were present in proximal convoluted tubule cells ( Figure 1A ). We also observed profound increases of renin protein abundance in kidneys of hepAGT Since the predominant function of AGT is to produce Ang II, we determined whether depletion of this precursor from hepatocytes would affect plasma and renal Ang II concentrations. Although hepatocyte-derived AGT was responsible for the majority of plasma AGT concentrations, 19, 26, 27 plasma Ang II concentrations were not different between hepAGT +/+ and hepAGT −/− mice. In contrast, a profound reduction of Ang II in kidney was evident in hepAGT −/− mice, compared with wildtype littermates ( Figure 1B ).
Inhibition of Megalin Disturbed AGT and Renin Homeostasis and Reduced Renal Ang II Production
Consistent with the report by Pohl et al, 25 we found AGT and renin were present in the subapical compartment of megalinpositive renal proximal tubules, and ACE was observed on brush borders ( Figure I in the online-only Data Supplement). Therefore, the essential renin-angiotensin components to produce Ang II were localized with megalin in renal proximal tubules. To investigate whether megalin regulates these renin-angiotensin components, megalin ASOs were applied to inhibit megalin.
Megalin was expressed most abundantly in kidney while being barely detectable in other organs in both male and female adult C57BL/6 mice fed normal diet or LDL receptor −/− mice fed Western diet ( Figure III in the online-only Data Supplement). Administration of megalin ASO efficiently suppressed megalin mRNA and protein abundance in kidney ( Figure IVA Figure 1C) . We observed striking increases of urine AGT and renin concentrations in mice receiving megalin ASO, whereas no major effects on plasma AGT and renin concentrations were detected (Figure VC through F in the online-only Data Supplement). In agreement with our observation in mice with hepatocytespecific deficiency of AGT, inhibition of megalin led to pronounced reduction of renal Ang II concentrations without influence on plasma Ang II concentrations ( Figure 1D ).
Inhibition of Megalin Attenuated Hypercholesterolemia-Induced Atherosclerosis
Our previous studies demonstrated that hepatocyte-specific deficiency of AGT led to pronounced reductions of atherosclerotic lesion area in mice. 26, 27 Since Ang II production in kidney is regulated by megalin, we examined the involvement of megalin in atherosclerosis. Both male and female LDL receptor −/− mice were injected subcutaneously with vehicle (PBS only), control ASO, or Gen 2.5 megalin ASO once every week for 13 weeks. Western diet feeding started 1 week after the first injection and continued for 12 weeks. Inhibition of megalin did not affect plasma total cholesterol concentrations or lipoprotein-cholesterol distributions (Figure 2A and B). En face analysis revealed reductions of atherosclerotic lesions in megalin ASO-injected mice in both male and female mice ( Figure 2C ). To validate this result, a second Gen 2.5 megalin ASO was developed, which targeted a different sequence of mouse megalin mRNA. A pronounced amelioration of atherosclerosis was also observed with administration of this second megalin ASO ( Figure VI in the online-only Data Supplement), providing consistent evidence that inhibition of megalin reduced development of atherosclerosis.
We also measured atherosclerotic lesions in the aortic root. Consistent with our findings by en face analysis, atherosclerotic lesions in the aortic root were smaller in mice injected with megalin ASO, compared with mice injected with vehicle ( Figure VII in the online-only Data Supplement). Despite the difference of lesion size between mice injected with vehicle and megalin ASO, the major cell type in atherosclerotic lesions of both groups was the lipid-laden macrophages as demonstrated by Oil Red O staining and immunostaining of CD68 (Figures VIII and XI in the online-only Data Supplement).
AGT has been implicated as an acute phase protein.
32
A previous study reported that hepatocyte-specific gp130 deficiency in apolipoprotein E deficient mice reduced atherosclerotic lesions, accompanied by reduced plasma serum amyloid A concentrations. 33 We measured plasma concentrations of serum amyloid A, but did not detect differences of this acute phase protein marker between hepAGT +/+ and hep-AGT −/− mice, and between vehicle and megalin ASO-injected mice fed Western diet (Figure X in the online-only Data Supplement).
Discussion
The present study reports 2 novel findings. First, inhibition of megalin reduces hypercholesterolemia-induced atherosclerosis. Second, renal, rather than plasma, Ang II contributes to the development of atherosclerosis.
Since leukocyte infiltration is a prominent feature of atherosclerosis, [34] [35] [36] it was hypothesized that the reninangiotensin activation in leukocytes would contribute to atherosclerosis. This hypothesis was negated by previous studies that AGT deficiency in leukocytes had no effects on atherosclerosis, 27 deficiency of renin or ACE in leukocytes only led to modest reduction of atherosclerosis, 37, 38 and AT1a receptor deficiency on leukocytes had no effects 37, 39, 40 or modest effect on atherosclerosis. 41 As AT1a receptor is abundant on endothelial and smooth muscle cells of the vasculature, 42 another widely circulated view persists that Ang II contributes to atherosclerosis by direct provocation of AT1a receptor on resident cells in vasculature. This hypothesis was not substantiated by our studies demonstrating that AT1a receptor deletion on either endothelial cells or smooth muscle cells had no effects on atherosclerosis. 43 Therefore, the major source for Ang II to promote atherosclerosis is not in the vascular wall or the circulation.
It is well recognized that AGT synthesized by liver, renin by kidney and ACE by lung contribute to their presence in circulation. 5, 26, 27, [44] [45] [46] However, it is unclear whether these organs provide each component to plasma to produce Ang II that contributes to physiological and pathophysiological functions, or they are predominantly transported through blood flow to target organs to facilitate local production of Ang II. Remarkably, kidney expresses AGT mRNA in S3 segment, 25, 47, 48 but AGT protein only accumulates in S1 and S2 segments of proximal convoluted tubules. 19 The function of AGT in S3 segment, if any, remains unclear. The molecular weight of AGT is ≈50 kDa. The glomerular permeability of AGT in vivo was observed using multiphoton microscopy. 49 After filtration, AGT is retained in proximal convoluted tubules and becomes the primary source of intrarenal AGT protein. 19 Our findings also confirm that liver is not only the major provider of AGT in plasma but also the source of AGT protein in kidney. Hepatocyte-derived AGT did not affect plasma Ang II concentrations, but had a profound influence on Ang II concentrations in kidney. Given that Ang II concentrations in kidney are far higher than concentrations in plasma, [12] [13] [14] 50 and depletion of AGT in plasma reduced renal rather than plasma Ang II concentrations, we hypothesize that kidney is an important organ for AGT derived from liver to produce Ang II.
We confirmed that all the components needed for Ang II production were present in proximal tubules. Since these renin-angiotensin components to produce Ang II are localized with megalin in proximal tubules, we presumed that megalin can regulate Ang II production in kidney. Our studies clearly showed that reduction of megalin by ASOs ablated both AGT and renin accumulation from proximal tubules, which support the notion that megalin plays an important role in retaining intratubular AGT and renin. Diminished accumulation of both AGT and renin in proximal convoluted tubule cells by megalin ASOs did not lead to profound reductions of plasma AGT or renin concentrations despite their substantial losses in urine. Similar losses occur in patients with Dent disease or Lowe syndrome in whom reabsorption by megalin is impaired, implicating human relevance of our findings in mice. 51 These results are consistent with endocytosed AGT and renin in proximal convoluted tubules being processed locally. Reduction of megalin led to ≈70% reduction of renal Ang II concentrations, without influence on plasma concentrations. These findings demonstrate that megalin plays a crucial role in maintaining AGT and renin homeostasis in kidney, which orchestrates the crosstalk of intrarenal renin-angiotensin components to determine Ang II production locally. Pronounced reductions of atherosclerosis were observed in hepAGT −/− mice 26, 27 and mice administered megalin ASOs, although their plasma Ang II concentrations were not different compared with their relative controls. These data support that renal, Figure 2 . Inhibition of megalin reduced hypercholesterolemia-induced atherosclerosis. A and D, Plasma total cholesterol concentrations in mice were measured using an enzymatic colorimetric method in mice fed Western diet for 12 wk. N=9-10/group. B and E, Lipoprotein distributions of cholesterol in plasma were determined using fast protein liquid chromatography (FPLC) size exclusion chromatography. N=4/group. C and F, Percent atherosclerotic lesion area was measured using an en face technique. N=9-10/group. *P<0.001 (C) or P=0.002 (F) by 1-way ANOVA followed by Holm-Sidak method. ASO indicates antisense oligonucleotides; HDL, high-density lipoprotein; LDL, low-density lipoprotein; and VLDL, very-low-density lipoprotein.
rather than the systemic renin-angiotensin activation, is the contributor to the development of atherosclerosis. Because serum amyloid A, a well-established biomarker of systemic inflammatory stress, was unchanged in hepAGT −/− mice or mice administered megalin ASO, the mechanisms whereby renal Ang II contributes to atherosclerosis may not be via increases in systemic inflammation.
In summary, either deletion of AGT or inhibition of megalin profoundly reduced Ang II production in kidney and was associated with pronounced reduction of atherosclerosis. These data support an important role of megalin in intrarenal renin-angiotensin homeostasis and atherosclerosis, and indicate kidney as a primary source of Ang II to promote atherosclerosis. This effect is accomplished via megalin integrating with the renin-angiotensin components in proximal tubules, providing rationale for future studies to determine the mechanisms by which renal Ang II contributes to atherosclerosis.
